Browse > Article
http://dx.doi.org/10.5012/bkcs.2013.34.11.3284

Pentafluorophenylprophyl Ligand-based Liquid Chromatography-Tandem Mass Spectrometric Method for Rapid and Reproducible Determination of Metformin in Human Plasma  

Yang, Jeong Soo (Clinical Trial Center, Clinical Research Institute, Samsung Medical Center)
Oh, Hyeon Ju (Department of Laboratory Medicine and Genetics, Samsung Medical Center)
Jung, Jin Ah (Department of Clinical Pharmacology and Therapeutics, Samsung Medical Center)
Kim, Jung-Ryul (Department of Clinical Pharmacology and Therapeutics, Samsung Medical Center)
Kim, Tae-Eun (Department of Clinical Pharmacology and Therapeutics, Samsung Medical Center)
Ko, Jae-Wook (Department of Clinical Pharmacology and Therapeutics, Samsung Medical Center)
Lee, Soo-Youn (Department of Laboratory Medicine and Genetics and Department of Clinical Pharmacology and Therapeutics, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Huh, Wooseong (Department of Medicine and Department of Clinical Pharmacology, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Publication Information
Abstract
This paper describes first development and validation of pentafluorophenylprophyl ligand-based liquid chromatography coupled to tandem mass spectrometry (PFPLC-MS/MS) method to determine metformin, a highly polar compound, in human plasma. Metformin and Phenformin (internal standard) were extracted from human plasma 50 ${\mu}L$ with a single-step protein precipitation. The chromatographic separation was performed using a linear gradient elution of mobile phase involving 5.0 mM ammonium formate solution with 0.1% formic acid (A) and acetonitrile (B) over 3.0 min of run time on a Phenomenex Luna PFP column. The detection was performed using a triple-quadrupole tandem mass spectrometer (Waters Quattro micro) with electrospray ionization in the mode of positive ionization and multiple-reaction monitoring (MRM). The developed method was validated with 5.0 ng/mL of lower limit of quantification (LLOQ). The calibration curve was linear over 5-3000 ng/mL of the concentration range ($R^2$ > 0.99). The specificity, selectivity, carry-over effect, precision, accuracy and stability of the method met the acceptance criteria. The method developed in this study had had rapidness, simplicity and ruggedness. The reliable method was successfully applied to high throughput analysis of real samples for a practical purpose of a pharmacokinetic study.
Keywords
Metformin; Liquid chromatography-tandem mass spectrometry; Pentafluorophenylpropyl stationary phase; Pharmacokinetic study; Human plasma;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Scheen, A. J.; Lefebvre, P. J. Drugs 1998, 55(2), 225.   DOI   ScienceOn
2 Bailey, C. J.; Day, C. Pract. Diab. Int. 2004, 21(3), 115.   DOI   ScienceOn
3 Krentz, A. J.; Bailey, C. J. Drugs 2005, 65(3), 385.   DOI   ScienceOn
4 Liu, A.; Coleman, S. P. J. Chromatogr. B 2009, 877, 3695.   DOI   ScienceOn
5 Ding, C.-G.; Zhou, Z.; Ge, Q.-H.; Zhi, X.-J.; Ma, L.-L. Biomed. Chromatogr. 2007, 21, 132.   DOI   ScienceOn
6 Chen, L.; Zhou, Z.; Shen, M.; Ma, A. J. Chromatogr. Sci. 2011, 49(2), 94.   DOI   ScienceOn
7 Hsieh, Y.; Galviz, G.; Hwa, J. J. Bioanalysis 2009, 1, 1073.   DOI   ScienceOn
8 Zhang, W.; Han, F.; Zhao, H.; Lin, Z. J.; Huang, Q. M.; Weng, N. Biomed. Chromatogr. 2012, 26, 1163.   DOI   ScienceOn
9 Zhang, L.; Tian, Y.; Zhang, Z.; Chen, Y. J. Chromatogr. B 2007, 854, 91.   DOI   ScienceOn
10 Georgita, C.; Albu, F.; David, V.; Medvedovici, A. J. Chromatogr. B 2007, 854, 211.   DOI   ScienceOn
11 Zhang, X.; Peng, Y.; Wan, P.; Yin, L.; Wang, G.; Sun, J. J. Chromatogr. Sci. 2013, 1, doi:10.1093/chromsci/bms204.
12 Sharma, K.; Pawar, G.; Yadam, S.; Giri, S.; Rajagopal, S.; Mullangi, R. Biomed. Chromatogr. 2013, 27(3), 356.
13 Jung, J. A.; Kim, J. R.; Kim, S. R.; Kim, T. E.; Lee, S. Y.; Ko, J. W.; Huh, W. Clin. Drug Invest. 2012, 32, 799.   DOI   ScienceOn
14 US Food and Drug Administration, Guidance for Industry: Bioanalytical Method Validation, Centre for Drug Evaluation and Research, Rockville, MD, 2001, http://www.fda.gov/cder/guidance/4252fnl.pdf
15 Lee, S. H.; Kwon, K. I. Arch. Pharm. Res. 2004, 27(7), 806.   DOI   ScienceOn
16 Guideline on the investigation of bioequivalence. European Medicines Agency, 2010.
17 Bardin, C.; Nobecourt, E.; Larger, E.; Chast, F.; Treluyer, J. M.; Urien, S. Eur. J. Clin. Pharmacol. 2012, 68(6), 961.   DOI   ScienceOn